Microbiome in Inflammatory Lung Diseases
Editat de Gaurav Gupta, Brian G. Oliver, Kamal Dua, Alisha Singh, Ronan MacLoughlinen Limba Engleză Hardback – 29 mar 2022
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 1175.18 lei 6-8 săpt. | |
| Springer Nature Singapore – 30 mar 2023 | 1175.18 lei 6-8 săpt. | |
| Hardback (1) | 953.65 lei 39-44 zile | |
| Springer Nature Singapore – 29 mar 2022 | 953.65 lei 39-44 zile |
Preț: 953.65 lei
Preț vechi: 1254.80 lei
-24% Nou
Puncte Express: 1430
Preț estimativ în valută:
182.52€ • 192.55$ • 152.10£
182.52€ • 192.55$ • 152.10£
Carte tipărită la comandă
Livrare economică 30 decembrie 24 - 04 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789811689567
ISBN-10: 9811689563
Pagini: 377
Ilustrații: XIV, 377 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.72 kg
Ediția:1st ed. 2022
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore
ISBN-10: 9811689563
Pagini: 377
Ilustrații: XIV, 377 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.72 kg
Ediția:1st ed. 2022
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore
Cuprins
Introduction to Lung Diseases.- Introduction to Microbiome.- Role of Microbiome in Inflammation.- The interplay of microbiome, inflammation, and immunity in inflammatory lung diseases.- Microbiome in Asthma.- Microbiome in Chronic Obstructive Pulmonary Disease.- Microbiome in Asthma-COPD Overlap syndrome (ACO).- Microbiome in ARDS (Acute Respiratory Distress Syndrome).- Role of brain-gut- microbiome axis in Depression co-morbid with COPD or Asthma.- Microbiome in Lung Cancer.- Microbiome in Pulmonary Tuberculosis.- Lung Microbiome: Friend or Foe of Mycobacterium tuberculosis.- Microbiome in Idiopathic Pulmonary Fibrosis. Microbiome in SARS-Cov2 (Covid-19).- Status of the microbiome in SARS-Cov2 (Covid-19).- Microbiome in Influenza-A Virus Infection.- Microbiome in Upper Respiratory Tract Infection (URTI).- Challenges in understanding the lung microbiota.- Microbiome in Inflammatory Lung Diseases: Challenges and Future Prospects.- Microbiota targeted via nanotechnology for lung cancer therapy: Challenges and future perspectives.
Notă biografică
Dr. Gaurav Gupta is an Associate Professor in the School of Pharmacy at the Suresh Gyan Vihar University (SGUV), Jaipur, Rajasthan, India. He has more than eleven years of experience in molecular and biochemical pharmacology, including respiratory diseases and cancer biology by employing experimental animal models to understand the cellular and molecular mechanism. Dr. Gupta is dedicated to improving outcomes in healthcare through his initiatives in pharmacology and phytochemistry research and effective teaching in the field of Pharmaceutical Sciences. Dr. Gupta has more than 300 research and review articles in peer-reviewed international journals and is co-author of one book. He is a member of various national and international societies.
Prof. Brian G. Oliver is currently the co-director of the Respiratory, Sleep, Environmental and Occupational Health clinical academic group of Maridulu Budyari Gumal, the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), A NHMRC AHRTC. He is a translational researcher who aims to identify and develop new ways of treating respiratory diseases. His scientific training began at the National Heart and Lung Institute, UK, where he mastered the isolation and in-vitro culture of several types of human lung cells. He then had further training in both molecular biology (University of Leeds) and then respiratory virology at Imperial College, UK, before commencing his PhD at The University of Sydney. He now leads the Respiratory Cellular and Molecular Biology Group with laboratory facilities located at both UTS and the Woolcock Institute. The work from his group is recognised to be amongst the best in the world, evidenced by selection for presentation at symposia at both national and large international conferences as well as resulting in prestigious publications.
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
Mrs. Alisha Singh is an Assistant Professor in the School of Pharmacy, Suresh Gyan University, Jaipur, Rajasthan, India. She has been a part of multiple funded projects as a Research Intern at TNMC and BYL Nair Ch. Hospital, Mumbai. Her total work experience is of 4 years which includes working with Cipla Ltd as a Medical Advisor. Her research interests include cost analysis studies, health economics, and drug utilization studies.
Dr. Ronan MacLoughlin is currently Associate Director of R&D, Science and Emerging Technologies in Aerogen Limited. Dr. MacLoughlin has more than 20 years of experience in Respiratory Drug Delivery with several nebulizers, and accessory product launches over that time. He has responsibility for new product development, establishing and exploiting the science underpinning respiratory drug delivery, and identifying new and potentially disruptive emerging technologies. To this end, he has developed multiple technologies and products with several patents granted and pending, that cover the range of drug, device, drug/device combination products, patient interventions and patient interfaces. Dr. MacLoughlin currently serves as chair of the Industry Representative Group in CURAM, the Science Foundation Ireland center for the development of the next generation of smart medical devices, and sits on the board, (previously chair) of the Medical and Engineering Technologies Center (MET), the Enterprise Ireland Technology Gateway. Additionally, he is currently chair of the Paediatric and Cystic Fibrosis working group within the International Society for Aerosols in Medicine (ISAM). Finally, Dr. MacLoughlin holds the position of adjunct Associate Professor in Trinity College Dublin (School of Pharmacy and Pharmaceutical Sciences), and Senior Honorary lecturer in the Royal College of Surgeons, Ireland (School of Pharmacy & Biomolecular Sciences).
Prof. Brian G. Oliver is currently the co-director of the Respiratory, Sleep, Environmental and Occupational Health clinical academic group of Maridulu Budyari Gumal, the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), A NHMRC AHRTC. He is a translational researcher who aims to identify and develop new ways of treating respiratory diseases. His scientific training began at the National Heart and Lung Institute, UK, where he mastered the isolation and in-vitro culture of several types of human lung cells. He then had further training in both molecular biology (University of Leeds) and then respiratory virology at Imperial College, UK, before commencing his PhD at The University of Sydney. He now leads the Respiratory Cellular and Molecular Biology Group with laboratory facilities located at both UTS and the Woolcock Institute. The work from his group is recognised to be amongst the best in the world, evidenced by selection for presentation at symposia at both national and large international conferences as well as resulting in prestigious publications.
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
Mrs. Alisha Singh is an Assistant Professor in the School of Pharmacy, Suresh Gyan University, Jaipur, Rajasthan, India. She has been a part of multiple funded projects as a Research Intern at TNMC and BYL Nair Ch. Hospital, Mumbai. Her total work experience is of 4 years which includes working with Cipla Ltd as a Medical Advisor. Her research interests include cost analysis studies, health economics, and drug utilization studies.
Dr. Ronan MacLoughlin is currently Associate Director of R&D, Science and Emerging Technologies in Aerogen Limited. Dr. MacLoughlin has more than 20 years of experience in Respiratory Drug Delivery with several nebulizers, and accessory product launches over that time. He has responsibility for new product development, establishing and exploiting the science underpinning respiratory drug delivery, and identifying new and potentially disruptive emerging technologies. To this end, he has developed multiple technologies and products with several patents granted and pending, that cover the range of drug, device, drug/device combination products, patient interventions and patient interfaces. Dr. MacLoughlin currently serves as chair of the Industry Representative Group in CURAM, the Science Foundation Ireland center for the development of the next generation of smart medical devices, and sits on the board, (previously chair) of the Medical and Engineering Technologies Center (MET), the Enterprise Ireland Technology Gateway. Additionally, he is currently chair of the Paediatric and Cystic Fibrosis working group within the International Society for Aerosols in Medicine (ISAM). Finally, Dr. MacLoughlin holds the position of adjunct Associate Professor in Trinity College Dublin (School of Pharmacy and Pharmaceutical Sciences), and Senior Honorary lecturer in the Royal College of Surgeons, Ireland (School of Pharmacy & Biomolecular Sciences).
Textul de pe ultima copertă
This book reviews the role of the lung microbiome in the development and progression of lung diseases. It deals with the role of microbiota dysbiosis in influencing host defense and immunity leading to resistance, colonization, and disease exacerbation. The book delineates the complex interaction between pathogen and lung residual microbiota during disease conditions. It further highlights the potential role of lung microbiota as the key modulator of lung carcinogenesis and immune response against cancer cells. Lastly, it reviews technological developments for unraveling the lung microbiome that profoundly impacts clinical diagnostics. This book is an essential resource for the scientists working in pulmonary diseases, pharmaceutical & clinical sciences, and pulmonary clinicians.
Caracteristici
Explore the potential role of microbiota in the pathogenesis of lung diseases Discusses challenges in understanding lung microbiota in disease states Reviews the influence of environment and host interactions on lung microbiome and composition